NCT02114658View on ClinicalTrials.gov

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

April 15, 2014

Primary Completion Date

February 23, 2015

Study Completion Date

August 2, 2016

Conditions

Thyroid Carcinoma

Interventions

DRUG

Sorafenib (Nexavar,BAY43-9006)

Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle

Trial Locations (5)

650-0011

Kobe

390-8621

Matsumoto

113-8603

Bunkyo-ku

135-8550

Koto-ku

545-8586

Osaka

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY

NCT02114658 - Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients | Biotech Hunter | Biotech Hunter